Skip to content
Riskpilot
← Back to search
Sign in
Get full access
ROSE PHARMA A/S
A/S
Dissolved
CVR 27174965
Universitetsparken 7, 4000
Roskilde
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
·
NACE 721900
Est. 2003 · 23 years old
— employees
Monitor
Share
Denmark
/
Companies
/
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
/
ROSE PHARMA A/S
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Former (8)
CL
Cora Louise Madsen
Management
Management
2003 – 2003
LA
Lise Abildgaard Ryberg
Management
Management
2004 – 2005
JO
Johan Olav Svensson
Founder
Founder
2003 – 2020
EK
Enda Kenny
Chief Executive Officer
Chief Executive Officer
2007 – 2012
CT
Claes Tomas Post
Management
Management
2003 – 2005
LF
Lars Folke Henrik Nilsson
Chief Executive Officer
Chief Executive Officer
2006 – 2007
Si
Sahltech i Göteborg AB
Founder
Founder
2003 – 2020
CT
Claes Tomas
Management
Management
2003 – 2003
Board of directors
Non-executive oversight
Name
Role
Member since
Former (10)
CW
Charles Woler
Board of Directors
Board of Directors
2007 – 2012
MF
Michael Forer
Chairman
Chairman
2012 – 2018
JL
Jeremy Laurence Curnock Cook
Board of Directors
Board of Directors
2005 – 2007
OG
Olof Gustav Paulus Isaksson
Board of Directors
Board of Directors
2006 – 2012
TB
Tamas Bartfai
Board of Directors
Board of Directors
2004 – 2007
TW
Thue Walter Schwartz
Board of Directors
Board of Directors
2003 – 2004
JJ
John-Olov Jansson
Board of Directors
Board of Directors
2003 – 2007
HT
Hans Thalsgård Schambye
Chairman
Chairman
2006 – 2012
CK
Christian Karsten Hansen
Board of Directors
Board of Directors
2007 – 2012
FS
Florian Schønharting
Board of Directors
Board of Directors
2012 – 2015
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Leif Helth Jensen
Individual
5–9.99%
5–9.99%
2016
Eli Lilly and Company
Individual
10–14.99%
10–14.99%
2016
NORDIC BIOTECH K/S
Company
33.33–49.99%
33.33–49.99%
2016
Rosetta Capital I, LP
Individual
20–24.99%
20–24.99%
2016
Bolagsstifterne BOVRO AB
Individual
5–9.99%
5–9.99%
2016
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on ROSE PHARMA A/S
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network